My research is focused on developing fluid-based biomarkers for detecting and staging neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, neuromuscular diseases, and long-term effects of traumatic brain injury. We are actively working on developing biomarkers in people with Down syndrome, who have very high risk for Alzheimer’s disease and in animal models of Alzheimer’s disease with the MODEL-AD consortium. We are actively engaged in clinical trials using biomarkers for participant selection, target engagement, and primary and secondary outcomes of efficacy. We focus on biobanking and basic proteomic assays in the wet lab and computational classification algorithm development in the dry lab.